[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612997":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":11,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"DWJ1622","EXPERIMENTAL",null,[13,14],"Drug: DWJ1622","Drug: DWC202313, DWC202314",{"label":16,"type":10,"description":11,"interventionNames":17},"DWC202313, DWC202314",[13,14],[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","DWJ1622 (single oral dose) is administered in accordance with the study protocol.",[16,9],{"type":20,"name":16,"description":24,"armGroupLabels":25,"otherNames":11},"DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.",[16,9],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"SHIN","CONTACT","825508858","hbshin028@daewoong.co.kr",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":11,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"H Plus YANGJI Hospital","RECRUITING","Seoul","Gwanak-gu","08779","South Korea",{"type":41,"coordinates":42},"Point",[43,44],126.9784,37.566,{"lat":44,"lon":43},[47],{"name":48,"role":29,"phone":49,"phoneExt":11,"email":11},"Bae","8218778875",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100612997",false,"NCT07260851","Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of \"DWJ1622\" and Co-administration of \"DWC202313\" and \"DWC202314\" in Healthy Volunteers","Inclusion Criteria:\n\n* Over 19 year old\n* Healthy adult volunteers\n\nExclusion Criteria:\n\n* with a history of mental disorder\n* For female volunteers, those who are suspected of being pregnant or lactating",true,"ALL","19 Years",{"count":62,"type":63},40,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fasting conditions.",[69],"Healthy Volunteers","2025-12-09",{"date":72,"type":73},"2025-12-17","ACTUAL",{"date":75,"type":73},"2025-11-05",{"date":77,"type":63},"2026-05-30",{"name":5,"class":6},1]